TSE:IMV - IMV Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$7.50 +0.37 (+5.19 %)
(As of 12/12/2018 10:13 AM ET)
Previous CloseC$7.13
Today's RangeC$7.23 - C$7.50
52-Week RangeC$5.18 - C$9.49
Volume9,117 shs
Average Volume38,064 shs
Market CapitalizationN/A
P/E Ratio-16.63
Dividend YieldN/A
BetaN/A
IMV Inc., a clinical-stage company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is based in Halifax, Canada.

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolTSE:IMV
Previous Symbol
CUSIPN/A
Phone+1-902-4921819

Debt

Debt-to-Equity Ratio80.22
Current Ratio4.86
Quick Ratio4.57

Price-To-Earnings

Trailing P/E Ratio-16.63
Forward P/E Ratio-37.50
P/E GrowthN/A

Sales & Book Value

Annual SalesC$49,000.00
Price / Sales6,887.76
Cash FlowC$0.43 per share
Price / Cash Flow17.47
Book ValueC$0.25 per share
Price / Book30.36

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees33
Outstanding Shares45,000,000
Market CapC$0.00
OptionableNot Optionable

IMV (TSE:IMV) Frequently Asked Questions

What is IMV's stock symbol?

IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."

How were IMV's earnings last quarter?

Imv Inc (TSE:IMV) issued its earnings results on Friday, November, 2nd. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.06. The business had revenue of $0.13 million for the quarter, compared to analysts' expectations of $0.06 million. View IMV's Earnings History.

When is IMV's next earnings date?

IMV is scheduled to release their next quarterly earnings announcement on Tuesday, March 19th 2019. View Earnings Estimates for IMV.

What price target have analysts set for IMV?

2 analysts have issued 1 year target prices for IMV's shares. Their forecasts range from C$10.40 to C$12.00. On average, they anticipate IMV's stock price to reach C$11.20 in the next year. This suggests a possible upside of 49.3% from the stock's current price. View Analyst Price Targets for IMV.

What is the consensus analysts' recommendation for IMV?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMV.

Has IMV been receiving favorable news coverage?

Press coverage about IMV stock has trended positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IMV earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

Who are some of IMV's key competitors?

Who are IMV's key executives?

IMV's management team includes the folowing people:
  • Mr. Frederic Ors, Pres, CEO & Director (Age 44)
  • Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD, Chief Financial Officer (Age 53)
  • Dr. Gabriela Nicola Rosu M.D., Chief Medical Officer
  • Mr. Joseph Sullivan, Sr. VP of Bus. Devel.
  • Mr. Leeladhar Sammatur, VP of Process Devel. & Manufacturing

How do I buy shares of IMV?

Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately C$7.50.

What is IMV's official website?

The official website for IMV is http://www.imvaccine.com/.

How can I contact IMV?

IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.


MarketBeat Community Rating for IMV (TSE IMV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  96
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Featured Article: Cost of Equity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel